NAMPT for wound healing and promotion of hair growth and / or regeneration

By combining NAMPT and NMN/NR in hydrogels, leveraging NAD biosynthesis and growth factor signaling, the challenges of skin regeneration and hair growth are solved, achieving complete skin regeneration and hair growth in diabetes and elderly states, avoiding Scar and angiogenesis defects improve skin healing ability.

CN119013038APending Publication Date: 2024-11-22INNOVATIVE SURGICAL REGENERATION HOLDINGS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032707.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-01-27
Filing Date
2023-04-10
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively promote the complete regeneration of the skin, especially in diabetes and elderly states, where skin lesions heal and hair growth are challenging, and common treatments such as medications and surgery have side effects and incomplete regeneration effects.

Method used

By increasing NAD biosynthesis and growth factor signaling, using a combination of nicotinamide phosphoribose transferase (NAMPT) with its precursors such as nicotinamide single nucleotide (NMN) and nicotinamide nucleoside (NR) in hydrogels, To promote epithelial formation and hair follicle regeneration in wound models, use thermally sensitive hydrogels such as Pluronic-F127 as carriers, locally applied to accelerate wound healing and hair growth.

Benefits of technology

In non-diabetic, diabetic and elderly states, complete regeneration and hair growth of the skin are achieved, normal skin structure is restored, wound healing and hair follicle growth is enhanced, scar formation and angiogenesis defects are avoided, and skin regeneration ability is improved. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005072322170000071
    Figure BDA0005072322170000071
  • Figure BDA0005072322170000081
    Figure BDA0005072322170000081
  • Figure BDA0005072322170000251
    Figure BDA0005072322170000251
Patent Text Reader

Abstract

Described herein is a method of stimulating hair growth and / or regeneration in a subject. The method comprises contacting a target region of the skin of the subject with an effective amount of a hair growth or regeneration composition comprising nicotinamide phosphoribosyltransferase (NAMPT) protein, a bioactive peptide fragment thereof, a NAMPT analogue, a vector comprising a polynucleotide encoding a NAMPT protein, a NAMPT activator, or a combination thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Prior related applications

[0002] The present invention claims priority to US 63 / 481,962 filed on January 27, 2023, US 63 / 481,963 filed on January 27, 2023, and US 63 / 329,224 filed on April 8, 2022, the entire contents of which are incorporated herein by reference for all purposes.

[0003] Federally Sponsored Research Statement

[0004] This invention was made with government support under Grant No. 2P510DO11104-57 awarded by the National Institutes of Health. The government has certain rights in this invention. Technical Field

[0005] The present invention relates to effective therapies that promote rapid and regenerative healing outcomes anytime, anywhere. Specifically, local or topical application of NAMPT in combination with NMN and NR using Pluronic-F127 hydrogel or fibrin hydrogel is provided to accelerate wound healing by increasing NAD biosynthesis and growth factor signaling in wound models to promote epithelialization rather than scarring and contraction.

[0006] The present invention also relates to an effective therapy for promoting hair follicle growth and regeneration, and specifically provides the use of NAMPT in accelerating hair growth and promoting hair follicle regeneration. Background Art

[0007] The skin is the largest organ in the human body and is composed of several tissues and cell types: the epidermis, dermis, hair follicles, various glands such as sebaceous glands, vasculature, and stem cells. Skin injuries result in non-functional scar tissue characterized by the absence of normal skin architecture and its replacement by fibroblasts. Despite advances in enhancing wound closure and healing, there remains a great need for therapies that can fully regenerate the skin to a normal state.

[0008] Additionally, hair loss is a concern for many men and women. In many people, hair loss (i.e., alopecia) can lead to psychological problems such as embarrassment and / or depression. Although hair loss is more common in men (i.e., male pattern baldness or androgenic alopecia) than in women (i.e., female pattern hair loss), it is a significant problem for both men and women. Treatments for hair loss include administering medications such as minoxidil, finasteride, and dutasteride, or performing hair transplants.

[0009] Hair follicles are structures within the skin that are responsible for hair production. Hair follicles are composed of various cell types, including stem and progenitor cells, which contribute to hair production as well as skin repair and regeneration during skin damage. Boosting and enhancing hair follicles is one of the main goals of regenerative skin therapies.

[0010] Nicotinamide adenine dinucleotide (NAD) is essential for cellular metabolism. Insufficient NAD leads to impaired cellular energy production. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting biosynthetic enzyme in the salvage NAD synthesis pathway and is present both intracellularly and extracellularly. Extracellular NAMPT functions as a growth factor and cytokine and exhibits NAD biosynthetic activity. Summary of the invention

[0011] The present invention provides the use of NAMPT and related compounds in improving wound healing and / or stimulating hair growth and promoting hair follicle growth and / or regeneration.

[0012] The present invention combines an NAD producing enzyme that acts as both an enzyme and a growth factor / cytokine with an NAD precursor to create a synergistic combination in a hydrogel.

[0013] In one aspect of the present invention, the combination of NAMPT with NMN and NR in a hydrogel was demonstrated to regenerate normal skin in full-thickness skin defects without defects or scars.

[0014] In another aspect of the invention, a method of growing / regrowing hair using a composition having NAMPT and optionally adding NAD precursors such as NMN and NR is described.

[0015] The present invention demonstrates for the first time that NAMPT alone or in combination with NAD precursors (whose therapeutic effects are synergistic) is sufficient to regenerate all tissues of the skin. The inventors demonstrated this in non-diabetic, diabetic and elderly diabetic full-thickness excisional skin defect splint models to reproduce the pathophysiology of human skin defects. Elderly, diabetic and elderly diabetic states are characterized by a significant reduction in the skin's regenerative capacity and reduced angiogenesis at the skin defect site.

[0016] In one aspect of the present invention, a wound healing composition is described, which comprises a nicotinamide phosphoribosyltransferase (NAMPT) protein, an active peptide fragment thereof or a NAMPT analog, and a pharmaceutically acceptable topical carrier.

[0017] In another aspect of the present invention, a method of treating a skin wound is described. The method comprises applying a therapeutically effective amount of a composition described herein to a skin wound of a subject.

[0018] In another aspect of the present invention, a method for stimulating hair growth and / or regeneration in a subject is described. The method comprises contacting a target area of ​​the subject's skin with an effective amount of a hair growth or regeneration composition, wherein the composition comprises a nicotinamide phosphoribosyltransferase (NAMPT) protein, an active peptide fragment thereof, a NAMPT analog, a vector comprising a polynucleotide encoding the same, or a combination thereof.

[0019] As described in the methods herein, the composition comprises the NAMPT protein of SEQ ID NO:1.

[0020] As described in the methods herein, the composition comprises a NAMPT analog that is at least 70% identical to SEQ ID NO:1.

[0021] As described herein, the composition comprises a NAMPT activator, which is 3,6-dibromo-α-[(phenylamino)methyl]-9H-carbazole-9-ethanol (P7C3), 1-[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)-phenyl]-3-pyridin-4-ylmethyl urea (SBI-797812) or a combination thereof.

[0022] As described in the methods herein, the composition comprises a NAMPT protein and a NAMPT activator.

[0023] As described in the method herein, the composition comprises a vector comprising RNA encoding a NAMPT protein, and the NAMPT protein is as shown in SEQ ID NO:1.

[0024] As described in the methods herein, the composition further comprises an NAD precursor selected from the group consisting of: tryptophan, nicotinic acid (pyridine-3-carboxylic acid), nicotinamide (nicotinamide), nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR).

[0025] As described in the methods herein, the composition further comprises a pharmaceutically acceptable carrier, including a topical formulation.

[0026] As described in the methods herein, the pharmaceutically acceptable carrier comprises a hydrogel. As described in the methods herein, the hydrogel comprises a thermosensitive hydrogel. As described in the methods herein, the thermosensitive hydrogel is pluronic-F127.

[0027] As described in the methods herein, the target area of ​​skin is skin affected by hair loss. As described in the methods herein, the skin affected by hair loss is a portion of the subject's entire scalp.

[0028] As described herein, the method further comprises the step of promoting skin penetration in the target area using a skin penetration enhancer selected from a needle, an abrasive material, or application of high pressure to the skin.

[0029] As described herein, the method further comprises the step of creating a boundary around the target area to restrict the activity of NAMPT to be substantially within the target area.

[0030] As described herein, the topical carrier is a hydrogel. In one embodiment, the hydrogel may include a thermosensitive hydrogel. In one embodiment, the thermosensitive hydrogel is pluronic-F127.

[0031] As described in the composition herein, the composition may further comprise a NAMPT activator. In one embodiment, the NAMPT activator is 3,6-dibromo-[(anilino)methyl]-9H-carbazole-9-ethanol (P7C3), 1-[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)-phenyl]-3-pyridin-4-ylmethylurea (SBI-797812) or a combination thereof.

[0032] As described herein, the composition may further comprise an NAD precursor. In one embodiment, the NAD precursor is selected from tryptophan, nicotinic acid (pyridine-3-carboxylic acid), nicotinamide (nicotinamide), nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR).

[0033] As described in the method for treating a skin wound, wherein the skin wound is a diabetic skin wound.

[0034] As described in the method for treating skin wounds, wherein the composition has a per 1 mm 2 The surface area of ​​the skin wound contains at least 0.01 μg (microgram) of NAMPT protein to promote complete skin regeneration. In one embodiment, the composition contains at least 0.01 μg (microgram) of NAMPT protein per 1 mm 2 The skin wound surface area contains at least 0.05 μg (microgram) of NAMPT protein to promote complete skin regeneration.

[0035] As used herein, the terms "administer", "administration", "administering", etc., when used in conjunction with a therapeutic agent, refer to the delivery of a therapeutic agent to a subject, whereby the therapeutic agent has a positive effect on the subject or its targeted tissue or organ, i.e., has a therapeutic effect. The therapeutic agents described herein can be administered alone or in combination (simultaneously or consecutively) with other drugs. For example, the therapeutic agent can be administered in combination with a vaccine, an antibiotic, an antiviral agent, an anticancer agent, or an antitumor agent, or in combination with other treatment modalities such as herbal therapy, acupuncture, natural therapy, etc.

[0036] As used herein, the term "effective amount" generally refers to the amount of therapeutic agent administered to reduce, prevent or inhibit disease. The amount of each compound will vary and depends on known factors related to the article or use to which the therapeutic agent is applied.

[0037] As used herein, the term "immune response" refers to the activity of immune system cells when exposed to a stimulus, such as, but not limited to, an antigen. In some embodiments, the antigen may be derived from a Bartonella spp.

[0038] As used herein, the term "modulate" refers to upregulation (ie, activation or stimulation), downregulation (ie, inhibition or repression), or both, of a response.

[0039] As used herein, the term "pharmaceutically acceptable" refers to compounds, materials, compositions and / or dosage forms that are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions or other problems or complications, and have a reasonable benefit / risk ratio, according to the guidelines of the U.S. Food and Drug Administration and other agencies, within the scope of reasonable medical judgment. "Pharmaceutically acceptable carrier" as used herein refers to all components in a pharmaceutical preparation that promote the in vivo delivery of the composition. Pharmaceutically acceptable carriers include, but are not limited to, diluents, preservatives, binders, lubricants, disintegrants, swelling agents, fillers, stabilizers and combinations thereof.

[0040] Pharmaceutically acceptable carriers include any of a variety of excipients known and used in the art for delivering drugs, medicines, etc. to a subject. Here, pharmaceutically suitable carriers may be particularly suitable for delivery in topical applications, including but not limited to hydrogels, creams, lotions, shampoos, emollients, 85% ethanol / 15% ethylene glycol, ointments, sprays, oils, dressings, pastes, drops, ointments, liposomes, etc.

[0041] As used herein, the term "prodrug" refers to an agent, including compounds, nucleic acids or proteins that are converted into biologically active forms in vitro and / or in vivo. Prodrugs may be useful because, in some cases, they may be easier to administer than the parent compound. For example, a prodrug may be bioavailable by oral administration, while the parent compound cannot. The solubility of a prodrug in a pharmaceutical composition may also be improved compared to the parent drug. Prodrugs can be converted into the parent drug by various mechanisms, including enzymatic processes and metabolic hydrolysis. Harper, NJ (1962) Drug Latentiation in Jucker, ed. Progress in Drug Research, 4: 221-294; Morozowich et al., (1977) Application of Physical Organic Principles to Prodrug Design in EB Roche ed. Design of Biopharmaceutical Properties through Prodrugs and Analogs, APhA; Acad. Pharm. Sci.; EB Roche, ed. (1977) Bioreversible Carriers in Drug in Drug Design, Theory and Application, APhA; H. Bundgaard, ed. (1985) Design of Prodrugs, Elsevier; Wang et al., (1999) Prodrug approaches to the improved delivery of peptide drug, Curr.Pharm.Design.5(4):265-287; Pauletti et al., (1997) Improvement in peptide bioavailability: Peptidomimetics and Prodrug Strategies,Adv.Drug.Delivery Rev.27:235-256; Mizen et al., (1998). I.CarrierProdrugs,Pract.Med.Chem. 671 - 696; M. Asgharnejad (2000). Improving Oral Drug Transport Via Prodrugs, in G. L. Amidon, P. I. Lee and E. M. Topp, Eds., Transport Processes in Pharmaceutical Systems, Marcell Dekker, p. 185 - 218; Balant et al., (1990) Prodrugs for the improvement of drug absorption via different routes of administration, Eur. J. Drug Metab. Pharmacokinet., 15(2):143 - 53; Balimane and Sinko (1999). Involvement of multiple transporters in the oral absorption of nucleoside analogs, Adv. Drug Delivery Rev., 39(1 - 3):183 - 209; Browne (1997). Fosphenytoin (Cerebyx), Clin. Neuropharmacol. 20(1):1 - 12; Bundgaard (1979). Bioreversible derivatization of drugs--principle and applicability to improve the therapeutic effects of drugs, Arch. Pharm. Chemi. 86(1):1 - 39; H. Bundgaard, ed. (1985) Design of Prodrugs, New York: Elsevier; Fleisher et al., (1996) Improved oral drug delivery: solubility limitations overcome by the use of prodrugs, Adv. Drug Delivery Rev. 19(2):115 - 130; Fleisher et al., (1985) Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting, Methods Enzymol.112:360-81; Farquhar D et al., (1983) Biologically Reversible Phosphate-Protective Groups, J.Pharm.Sci., 72(3):324-325; Han, HK et al., (2000) Targeted prodrug design to optimize drug delivery, AAPS PharmSci., 2(1):E6; Sadzuka Y.(2000)Effective prodrug liposome and conversion to active metabolite,Curr.Drug Metab.,1(1):31-48;DMLambert(2000)Rationale and applications oflipids as prodrug carriers,Eur.J.Pharm.Sci.,11Suppl.2:S15-27;Wang,W.et al.,(1999)Prodrug approaches to the improved delivery ofpeptidedrugs.Curr.Pharm.Des., 5(4):265-87. .

[0042] As used herein, the term "subject" may include human subjects for medical purposes, such as prophylactic agents for treating existing diseases, disorders, conditions or preventing the onset of diseases, disorders or conditions, or animal subjects for medical, veterinary or development purposes. Suitable animal subjects include mammals, including but not limited to primates, such as humans, monkeys, apes, gibbons, chimpanzees, orangutans, macaques, etc.; bovines, such as cattle, bulls, etc.; ovines, such as sheep (sheep), etc.; caprines, such as goats, etc.; suids, such as pigs, hogs, etc.; equines, such as horses, donkeys, zebras, etc.; felines, including wild cats and domestic cats; canines, including dogs; lagomorphs, including rabbits, hares, etc.; and rodents, including mice, rats, guinea pigs, etc. The animal may be a transgenic animal. In some embodiments, the subject is a human, including but not limited to fetuses, newborns, infants, adolescents, and adult subjects. In addition, "subjects" may include patients suffering from or suspected of having a disease, disorder, or condition. Therefore, the terms "subject" and "patient" are used interchangeably herein. Subjects also include animal disease models (eg, rats or mice used in experiments, etc.).

[0043] As used herein, the term "therapeutic agent" refers to any substance used to restore or promote the health and / or wellbeing of a subject and / or to treat, prevent, alleviate, cure or diagnose a disease, disorder or condition.

[0044] As used herein, the terms "therapeutically effective" and "pharmacologically effective" are intended to quantify the amount of each drug to achieve the goal of reducing the severity of the disease while avoiding adverse side effects, such as those typically associated with alternative therapies. A therapeutically effective amount can be administered in one or more doses.

[0045] The term "effective amount" is intended to quantify the amount of an agent required to achieve an effect that is not a therapeutic effect. For example, while hair regrowth may be primarily for therapeutic purposes, hair growth may occur in non-disease contexts and thus may refer to an "effective amount" of an agent, rather than a "therapeutically effective amount."

[0046] As used herein, the terms "peptide", "polypeptide" and "protein" are used interchangeably and refer to compounds consisting of amino acid residues covalently linked by peptide bonds. Unless otherwise specified, a protein or peptide must contain at least four amino acids, and there is no limit to the maximum number of amino acids that can comprise a protein or peptide sequence. Polypeptides include any peptide or protein consisting of four or more amino acids interconnected by peptide bonds. As used herein, the term refers to both short chains, such as those commonly referred to in the art as peptides, oligopeptides and oligomers, and long chains, which are commonly referred to in the art as proteins, of which there are many types. "Polypeptide" includes, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, polypeptide variants, modified polypeptides, derivatives, analogs, fusion proteins, etc. The polypeptide includes a natural peptide, a recombinant peptide, a synthetic peptide, or a combination thereof.

[0047] As used herein, the terms "treatment", "treating", and the like refer to interventions performed to prevent the development of a disease or to alter the pathology or symptoms of a disease. Thus, "treatment" may refer to therapeutic treatment or prophylactic or preventative measures. In some embodiments, the treatment is used for therapeutic treatment. In some embodiments, the treatment is used for prophylactic or preventative treatment. People in need of treatment may include those who already have the disease, as well as those who need to prevent the disease. In some embodiments, the treatment is used for experimental treatment.

[0048] The details of one or more embodiments of the present invention are set forth in the attached specification below. Although any materials and methods similar or equivalent to those described herein may be used in the practice or testing of the present invention, preferred materials and methods are now described. According to the specification, other features, objects and advantages of the present invention will become apparent. Unless the context clearly provides otherwise, in the specification, the singular form also includes the plural form. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. In the event of a conflict, this specification shall prevail.

[0049] The present invention is further illustrated by the following non-limiting examples.

[0050] Unless the context dictates otherwise, when used in conjunction with the word "comprising" in a claim or the specification, the word "a" or "an" means one or more.

[0051] The term "about" refers to the stated value plus or minus the margin of error in measurement, or plus or minus 10% if no measurement method is specified.

[0052] The word "or" as used in the claims is intended to mean "and / or" unless explicitly stated to refer to only alternatives or the alternatives are mutually exclusive.

[0053] The terms "comprise," "have," "include," and "contain" (and variations thereof) are open-ended linking verbs that, when used in a claim, allow for the addition of additional elements.

[0054] The phrase "consisting of" is closed, excluding all other elements.

[0055] The phrase "consisting essentially of excludes additional essential elements but allows the inclusion of non-essential elements that do not materially change the nature of the invention.

[0056] This article uses the following abbreviations:

[0057]

[0058] BRIEF DESCRIPTION OF THE DRAWINGS

[0059] The above and other features of the present application will become apparent to those skilled in the art after reading the following description with reference to the accompanying drawings, wherein:

[0060] Figure 1A-B shows that (A) intradermal injection of NAMPT in mouse skin every 48 hours significantly promoted hair growth from 10 to 14 days compared with the control group, and (B) histological analysis showed an increase in hair follicles in the skin of NAMPT-treated mice compared with the control group.

[0061] Figure 2A -G: Fibroblast heterogeneity and the effects of NAMPT on diabetic wound fibroblasts. Figure 2A : UMAP shows fibroblast populations (clusters #0, #5, #10, and #12). Gene Ontology (GO) was used to determine pathway enrichment in different fibroblast subpopulations. Figure 2B : Cluster #0 fibroblasts are enriched for fibroblast proliferation and response to injury pathways, indicating that cluster #0 is the major fibroblast cluster of interest in this biological system. Figure 2C : Pathway enrichment in cluster #5 fibroblasts. Figure 2D : Pathway enrichment in cluster #10 fibroblasts. Figure 2E : Pathway enrichment in cluster #12 fibroblasts. Figure 2F : Violin plots showing differential expression of collagen genes in cluster #0 cells of NAMPT-treated diabetic wounds and control diabetic wounds. Figure 2G : Gene Ontology (GO) analysis showed that cluster #0 cells from NAMPT-treated diabetic wounds were significantly enriched in "extracellular matrix organization", "response to cytokines", and "regulation of cell migration" compared to control diabetic wounds. ***p < 0.001 adjusted by Wilcoxon rank sum test.

[0062] Figure 3A -C: Effects of NAMPT on undifferentiated epidermal cells in wounds of diabetic patients. Figure 3A : Violin plots showing differential expression of epidermal stem cell genes in cluster #1 cells from NAMPT-treated diabetic wounds and control diabetic wounds. Figure 3B : Gene Ontology (GO) analysis showed that cluster #1 cells from NAMPT-treated diabetic wounds were significantly enriched in the "response to wound" and "regulation of cell migration" pathways compared to control diabetic wounds. Figure 3C : Pathway analysis confirmed that the functions of cluster #1 undifferentiated epidermal cells include establishment of skin barrier, cell motility, and epithelial development. ***Adjusted p<0.001 by Wilcoxon rank sum test.

[0063] Figure 4A -D: Pseudo-temporal lineage trajectory analysis shows that NAMPT stimulates epidermal stem cells in diabetic wounds. Figure 4A : Plot cells from cluster #1 and sort them by pseudotime. Figure 4B: Trajectory divergence at branch point 2 leads to cell fate 1 or cell fate 2. Figure 4C : Heatmap shows that at branch point 2, there is a significant difference in the expression of genes leading to cell fate 1 versus cell fate 2 as a function of pseudotime (q<0.05). Cells from cell fate 1 show significantly higher levels of Krt5, Krt14, and Krt15. Figure 4D : Branching analysis revealed that cells from cell fate 1 showing elevated expression of Krt5, Krt14, and Krt15 belonged to NAMPT-treated diabetic patient wounds.

[0064] Figure 5A -D: Pathway analysis revealed differences between NAMPT-treated diabetic wounds and control diabetic wounds. Figure 5A : Differentially enriched pathways between NAMPT-treated diabetic wounds and control diabetic wounds are shown. Pathways enriched between NAMPT-treated diabetic wounds are in red, while pathways enriched in control diabetic wounds are in green. Figure 5B : Cellchat clusters are named CLA-CLR, corresponding to clusters #0-#17, respectively. UEC: undifferentiated epidermal cells. DEC: differentiated epidermal cells. VEC: vascular endothelial cells. Figure 5C : Shows WNT signaling between wound cell populations in control and diabetic patients. Figure 5D : Shows WNT ligand-receptor in wounds of control diabetic patients.

[0065] Fig. 6A -E: NAMPT improves skin regeneration. Full-thickness excisional wounds were generated and splinted in non-diabetic mice (A) and diabetic mice (db / db) (BE) and treated with NAMPT hydrogel or control solvent hydrogel. Hematoxylin and eosin staining was performed. Fig. 6A -B: Histology shows regeneration of the panniculus fasciae (arrow 1), intradermal fat (2), dermal appendage morphology (3: sebaceous glands, hair follicles), angiogenesis (4), and lack of collagen density / scar pattern in NAMPT hydrogel-treated wounds compared to control wounds. Figure 6C : Immunohistochemistry showed positive staining of β-catenin and keratin 15 in NAMPT-treated diabetic patient wounds. Fig.6D : In contrast, control wounds lacked β-catenin and keratin 15 staining. Fig. 6E : NAMPT significantly increased the percentage of positive staining area for keratin 15 (p=0.0166) and β-catenin (p=0.0332) in diabetic wounds compared with the control diabetic wounds (n=3) (t test).

[0066] Fig. 7A -C: Pseudo-temporal lineage trajectory analysis shows that NAMPT stimulates hair follicle formation. Fig. 7A : Cells involved in the keratin 79+ to Krt6+ transition are mapped and ordered by pseudotime. Figure 7B : The heatmaps confirmed that the plotted trajectories and pseudo-temporal directionality were biologically accurate. Figure 7C : Keratin 79+ progenitor cells and Krt6+ differentiated cells of hair follicles were present in wounds of NAMPT-treated diabetic patients, but not in wounds of control diabetic patients.

[0067] Fig. 8A -C: Pseudo-temporal lineage trajectory analysis shows that NAMPT stimulates sebaceous gland formation. Fig. 8A : Cells involved in sebaceous gland formation are mapped and sorted by pseudotime. Figure 8B : The heatmaps confirmed that the plotted trajectories and pseudo-temporal directionality were biologically accurate. Figure 8C : Krt5+ / Krt14+ progenitor cells and differentiated sebaceous gland Pparg+ / Fasn+ cells were present in wounds of NAMPT-treated diabetic patients but not in wounds of control diabetic patients.

[0068] Fig.9A -C: Pseudo-temporal lineage trajectory analysis reveals that NAMPT stimulates the Krt77+ cell population. Fig.9A : Cells participating in the formation of the Krt77+ cell population were plotted and sorted by pseudotime. Fig. 9B : The heatmaps confirmed that the plotted trajectories and pseudo-temporal directionality were biologically accurate. Fig. 9C : Krt5+ / Krt14+ progenitor cells and differentiated Krt77+ cells were present in wounds of NAMPT-treated diabetic patients but not in wounds of control diabetic patients.

[0069] Fig. 10A -C: Role of NAMPT in epidermal cell differentiation. Fig. 10A : Markers of epidermal differentiation and undifferentiated and differentiated cells are shown. During epidermal cell differentiation, undifferentiated basal cells characterized by Krt5+ / Krt14+ / Krt15+ markers differentiate into Krt1+ / Krt10+ spinous cells and finally differentiate into terminally differentiated keratinocytes (Cdsn+ / Lor+ / Ivl+). Fig. 10B : All epidermal cells from non-diabetic skin were mapped and sorted as a function of pseudotime. Fig. 10C: Heatmaps confirm that the plotted trajectories and pseudotime directionality are biologically accurate by plotting several markers as a function of pseudotime. High levels of Nampt were observed in early epidermal stem cells that express high levels of Krt5, Krt14, and Krt15. The pseudotime decrease in Nampt preceded the decrease in stem markers, indicating that Nampt is involved in the maintenance of stem cell properties (stemness). Interestingly, Nampt expression increased before the increase in Krt1 and Krt10 (markers of more differentiated epidermal cells), suggesting that Nampt is involved in the achievement of differentiation. Nampt completely loses expression in terminally differentiated epidermal cells, which have no intrinsic stem cell properties. DETAILED DESCRIPTION

[0070] The present invention provides a method for wound healing in a subject, stimulating hair growth and / or regeneration in the subject. The method comprises contacting a target area of ​​the subject's skin with an effective amount of a hair growth or regeneration composition, the composition comprising a nicotinamide phosphoribosyltransferase (NAMPT) protein, an active peptide fragment thereof, a NAMPT analog, a vector comprising a polynucleotide encoding a NAMPT protein, a NAMPT activator, or a combination thereof.

[0071] preparation

[0072] In some embodiments, the therapeutic agent is administered to a human, human patient, or subject.For purposes of the present invention, the phrase "active ingredient" generally refers to the therapeutic agent that is delivered as described herein.

[0073] Although the description of the formulations provided herein is primarily directed to formulations suitable for administration to humans, it will be understood by those skilled in the art that such therapeutic agents are generally suitable for administration to any other animal, e.g., non-human animals, such as non-human mammals. It is well known that the formulations suitable for administration to humans are modified to make the therapeutic agents suitable for administration to various animals, and veterinary pharmacologists with ordinary skills can design and / or perform such modifications only by ordinary (if any) experiments. Subjects to whom the formulations are intended to be administered include, but are not limited to, humans and / or other primates; mammals, including commercially relevant mammals, such as cattle, pigs, horses, sheep, cats, dogs, mice and / or rats; and / or birds, including commercially relevant birds, such as poultry, chickens, ducks, geese and / or turkeys.

[0074] The formulations of the therapeutic agents described herein can be prepared by any method known or later developed in the art of pharmacology. In general, such preparation methods include the steps of combining the active ingredient with an excipient and / or one or more other auxiliary ingredients, and then, if necessary and / or desired, dividing, shaping and / or packaging the product into the desired single or multiple dosage units.

[0075] The preparations according to the present invention can be prepared, packaged and / or sold in bulk, in a single unit dose and / or in a plurality of single unit doses. As used herein, a "unit dose" is a discrete amount of a pharmaceutical composition comprising a predetermined amount of an active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient to be administered to the subject and / or a convenient portion of such dosage, such as half or one-third of such dosage.

[0076] The relative amounts of active ingredient, pharmaceutically acceptable excipient and / or any other ingredients in the formulations according to the present invention will vary depending on the identity, size and / or condition of the subject being treated and the route of administration of the formulation. For example, the formulation may include 0.1% to 100%, such as 0.5% to 50%, 1-30%, 5-80%, or in some embodiments, at least 20%, at least 40%, at least 60%, or at least 80% (w / w) of the active ingredient.

[0077] The therapeutic agents of the present invention may be formulated using one or more excipients to: (1) increase stability; (2) allow for sustained or delayed release; (3) alter biodistribution; (4) alter the release profile of the therapeutic agent in vivo. Non-limiting examples of excipients include any and all solvents, dispersion media, diluents or other liquid solvents, dispersion or suspension aids, surfactants, isotonicity agents, thickeners or emulsifiers, and preservatives. Excipients of the present invention may also include, but are not limited to, lipid compounds, liposomes, fat nanoparticles, polymers, lipid complexes, core-shell nanoparticles, peptides, proteins, hyaluronidase, nanoparticle mimetics, and combinations thereof.

[0078] In some embodiments, the pharmaceutical composition or preparation of the present invention may be suitable for delivering the prescription dose of one or more therapeutic agents to cells, cell groups, organs or tissues, animals or humans. The method of incorporating therapeutic agents into pharmaceutical preparations is well known in the art. Determining the appropriate prescription dose of the pharmacologically active compound contained in the pharmaceutical preparation to achieve the desired biological results is within the technical level of ordinary practitioners in the art. Pharmaceutical preparations may include excipients, such as but not limited to adhesives, coatings, disintegrants, fillers, diluents, spices, pigments, lubricants, glidants, preservatives, adsorbents, sweeteners, conjugated linoleic acid (CLA), gelatin, beeswax, purified water, glycerol, any type of oil, including but not limited to fish oil or soybean oil, etc. Therapeutic agents and / or pharmaceutical preparations may include suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starch, cellulose derivatives, gelatin and polymers, such as polyethylene glycol. Those of ordinary skill in the art will also understand that the term also encompasses those therapeutic agents and / or pharmaceutical formulations that contain a mixture of two or more pharmacologically active compounds, which are administered, for example, as a combination therapy.

[0079] Pharmaceutical preparations according to the present invention can be prepared, packaged and / or sold in bulk, in a single unit dose and / or in multiple single unit doses. As used herein, "unit dose" refers to a discrete amount of a pharmaceutical preparation containing a predetermined amount of a therapeutic agent or other compound. The amount of the therapeutic agent can generally be equal to the dosage of the therapeutic agent administered to the subject and / or a convenient portion of such dosage, including but not limited to half or one-third of such dosage.

[0080] excipient

[0081] The formulation may additionally contain a pharmaceutically acceptable excipient, as used herein, which includes any and all solvents, dispersion media, diluents or other liquid solvents, dispersion or suspension aids, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, solid binders, lubricants, etc., to suit the specific dosage form desired. Remington's "Pharmacy Science and Practice", 21st edition, A.R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, MD, 2006; the entire text is incorporated herein by reference) discloses various excipients and known preparation techniques for pharmaceutical compositions. Unless any conventional excipient medium is incompatible with the substance or its derivatives, such as producing any undesirable biological effect or interacting with any other component of the pharmaceutical composition in other harmful ways, its use should be considered within the scope of the present invention.

[0082] In some embodiments, pharmaceutically acceptable excipients are at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% pure. In some embodiments, excipients are approved for human and veterinary use. In some embodiments, excipients are approved by the U.S. Food and Drug Administration. In some embodiments, excipients are pharmaceutical grade. In some embodiments, excipients meet the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia and / or the International Pharmacopoeia.

[0083] Pharmaceutically acceptable excipients for making pharmaceutical compositions include, but are not limited to, inert diluents, dispersing and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils. Such excipients may be optionally included in the pharmaceutical composition.

[0084] Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, the like, and / or combinations thereof.

[0085] Exemplary granulating and / or dispersing agents include, but are not limited to, potato starch, corn starch, tapioca starch, sodium starch glycolate, clay, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponges, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked polyvinyl pyrrolidone (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethylcellulose, cross-linked sodium carboxymethylcellulose (cross-linked carboxymethylcellulose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethylcellulose, magnesium aluminum silicate Sodium lauryl sulfate, quaternary ammonium salt ammonium compounds, etc., and / or combinations thereof.

[0086] Exemplary surfactants and / or emulsifiers include, but are not limited to, natural emulsifiers (e.g., gum arabic, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan gum, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, waxes, and lecithin), colloidal clays (e.g., bentonite [aluminum silicate] and [magnesium aluminum silicate]), long-chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, glyceryl monostearate triacetate, ethylene glycol distearate, glyceryl monostearate and propylene glycol stearate, polyvinyl alcohol), carbomers (e.g., carboxypolymethylene, polyacrylic acid, acrylic acid polymers and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., sodium carboxymethylcellulose, powdered cellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate Polyoxyethylene sorbitan Polysorbate Sorbitan monopalmitate Sorbitan monostearate Sorbitan tristearate Glyceryl monooleate, Sorbitan monooleate ), polyoxyethylene esters (such as polyoxyethylene monostearate Polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate and ), sucrose fatty acid esters, polyethylene glycol fatty acid esters (such as ), polyoxyethylene ether (such as lauryl alcohol polyoxyethylene ether ), polyvinyl pyrrolidone, diethylene glycol laurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, ethyl laurate, sodium lauryl sulfate, F 68, l88, cetrimide bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and / or their combinations.

[0087] Exemplary binders include, but are not limited to, starches (e.g., corn starch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol), natural and synthetic gums (e.g., acacia, sodium alginate, Irish moss extract, panwar gum, ghatti gum, psyllium husk gum, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, cellulose acetate, polyvinyl pyrrolidone, magnesium aluminum silicate, and larch arabinogalactan), alginate, polyethylene oxide, polyethylene glycol, inorganic calcium salt, silicic acid, polymethacrylate, wax, water, ethanol, etc., and combinations thereof.

[0088] Exemplary preservatives may include, but are not limited to, antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives and / or other preservatives. Exemplary antioxidants include, but are not limited to, alpha-tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium pyrosulfite and / or sodium sulfite. Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium ethylenediaminetetraacetate, dipotassium ethylenediaminetetraacetate, ethylenediaminetetraacetic acid, fumaric acid, malic acid, phosphoric acid, sodium ethylenediaminetetraacetate, tartaric acid and / or trisodium ethylenediaminetetraacetate. Exemplary antimicrobial preservatives include but are not limited to benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethanol, glycerol, hexetidine, imidazolidinyl urea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol and / or thimerosal. Exemplary antifungal preservatives include but are not limited to butylparaben, methylparaben, ethylparaben, propylparaben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate and / or sorbic acid. Exemplary alcohol preservatives include but are not limited to ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate and / or phenylethyl alcohol. Exemplary acidic preservatives include but are not limited to vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid and / or phytic acid. Other preservatives include, but are not limited to, tocopherol, tocopherol acetate, dexamethicone mesylate, cetyltrimethylammonium bromide, butylated hydroxyanisole (BRA), butylated hydroxytoluene (BHn), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANT Methylparaben, ll5, ll.NEOLONE TM , KATHON TM and / or

[0089] Exemplary buffers include, but are not limited to, citrate buffer solutions, acetate buffer solutions, and phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propionic acid, calcium levulinate, valeric acid, dicalcium phosphate, tricalcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, monopotassium phosphate-dipotassium phosphate-potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, disodium phosphate, monosodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethanol, the like, and / or combinations thereof.

[0090] Exemplary lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, silicon dioxide, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and the like, and combinations thereof.

[0091] Exemplary oils include, but are not limited to, almond, apricot, avocado, babassu, bergamot, black currant seed, boragecade, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazelnut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin), lavender, lemon, litsea cubeba, macadamia, mallow, mango seed, argan white meadowfoam seed, mink oil, nutmeg, olive, orange, tangerine, palm, palm kernel, peach kernel, peanut, poppy seed pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, sassafras, sea buckthorn, sesame, shea butter, silicone, soy, sunflower, tea tree, thistle, toon, vetiver, walnut, and wheat germ oil. Exemplary oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, polyethersiloxane 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and / or combinations thereof.

[0092] Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and / or perfuming agents can be present in the composition, according to the judgment of the formulator.

[0093] Dosage and Administration

[0094] Application

[0095] In some embodiments, a therapeutic agent and / or a pharmaceutical formulation comprising a therapeutic agent can be administered by one or more routes of administration.In some embodiments, the drug is administered enterally (into the intestine), transdermally, intravenously, intralesionally (into or directly into a local lesion), intrapulmonary (into the lung or its bronchi), diagnostically, intraocularly (into the eye), transtympanically (through or through the tympanic cavity), intravesical infusion, sublingually, nasogastrically (through the nose into the stomach), spinal, intracartilaginously (into the cartilage), insufllation (nasal spray), rectal, intravascularly (into one or more blood vessels), buccally (directed toward the cheek), dentally (directed toward one or more teeth), intratesticularly (inside the testicle), intratympanically (into the aurus media), transdermal, intrathoracic (in the chest cavity), submucosal, cutaneous, epidermal (applied to the skin), intradental, intramedullary (in the marrow cavity of a bone), intraperitoneal, epidural (in the dura mater), intramuscular (into a muscle), intralymphatic (in the lymph), iontophoresis (the movement of soluble salt ions into body tissues by means of an electric current), subcutaneous (under the skin), intragastric (in the stomach), nasal administration (through the nose), vaginal, intravenous, intrasinus, intraprostatic (in the prostate), soft tissue, intradural (in or under the dura mater), subconjunctival, oral (by mouth), hard Extramembranous, parenteral, intraduodenal (in the duodenum), intracisternal (in the cerebellomedullary cistern), periodontal, periarticular, biliary perfusion, intracoronary (in the coronary artery), intrathecal (in the cerebrospinal fluid at any level of the cerebrospinal cord), intrameningeal (in the meninges), intracavernous injection (into the pathological cavity), intracavitary (into the base of the penis), intrabiliary, subarachnoid, intracystic, ureteral (into the ureter), intratendon (into the tendon), intraauricular (in or through the ear), intracardiac (into the heart), enema, intraepidermal (to the epidermis), ventricular (in the ventricle), intramyocardial ( Intramyocardial), intratubular (in the small tubes of an organ), vaginal, sublabial, intracavernous (in the expandable spaces of the corpora cavernosa of the penis), intradermal (into the skin itself), intravitreal (through the eye), perineurial, cardiac perfusion, irrigation (used to clean or irrigate an open wound or body cavity), ear drops, intratracheal, intraosseous infusion (into the bone marrow), sacral block, intrauterine, intratracheal (through the tracheal wall), intra-articular, intracavitary (inside the cornea), intracervical, extracorporeal, intraspinal (inside the spine), transmucosal (through the mucosa), topical, photopheresis, oropharyngeal (directly to the mouth and pharynx intravenous (into a vein), intraamniotic, intraluminal (into a joint), intraluminal (into a lumen), intracavitary (into a tube), intravenous (into a vein), intramyocardial (into a synovial cavity), intraluminal (into a lumen), intracavitary (into a synovial cavity ...Intraileal (in the distal portion of the small intestine), intraesophageal (to the esophagus), extra-amniotic administration, hemodialysis, intragingival (in the gums), intratumoral (in a tumor), eye drops (on the conjunctiva), laryngeal (directly in the throat), urethral (into the urethra), intravaginal administration, intraperitoneal (infusion or injection into the peritoneum), respiratory (by mouth or nasal inhalation for local or systemic effect in the respiratory tract), intradiscal (in the intervertebral disc), intraocular (to the outside eye) and / or intraovarian (in the ovary) administration.

[0096] In some embodiments, the therapeutic agent and / or pharmaceutical formulation comprising the therapeutic agent can be administered intraarticularly, extracorporeally, intrabronchially, intracervically, intrasinusally, intratracheally, enterally, epidurally, intraperitoneally, intrabiliaryally, intracapsularly, oropharyngeally, interstitially, intracardially, intracartilaginously, intracaudally, intracerebrally, intracavitarily, intracorneally, intraperitoneally, intraperitoneally, intracoron ... administration), intracisternal administration, intracranial administration, intracranial administration, intradermal administration, intralesional administration, intratympanic administration, intragingival administration, intraocular administration, intradiscal administration, intraductal administration, intraduodenal administration, ocular administration, intradural administration, intradermal administration, intraesophageal administration, nasogastric administration, nasal administration, laryngeal administration, intraventricular administration, intragastric administration, intrahepatic administration, intracavity administration, intravitreal administration, intravesical administration, intralymphatic administration, intramammary administration, intramedullary administration, intraspinal administration, intramuscular administration, intranodular administration, intraovarian administration, intraperitoneal administration, intrapleural administration, intraprostatic administration, intraluminal administration administration, intraspinal administration, intrasynovial administration, intratendinous administration, intratesticular administration, subconjunctival administration, intracerebroventricular administration, epidermal administration, intravenous administration, retrobulbar administration, periarticular administration, intrathoracic administration, subarachnoid administration, intratubular administration, periodontal administration, transtympanic administration, tracheal administration, intratumoral administration, vaginal administration, urethral administration, intrauterine administration, oral administration, gastrointestinal administration, parenteral administration, sublingual administration, ureteral administration, transdermal administration, epidural administration, transmucosal administration, perineural administration, transdermal administration, rectal administration, soft tissue administration, intraarterial administration, subcutaneous administration, topical administration, extra-amniotic administration, ear drops or intravesical infusion.

[0097] The therapeutic agents and / or pharmaceutical preparations of the present invention can be administered orally, but any suitable route of administration can be used to provide an effective amount of the drug of the chemical composition described herein to the subject. For example, oral, rectal, topical, parenteral, ophthalmic, pulmonary, nasal, etc. can be used. Dosage forms include tablets, lozenges, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, etc. In certain embodiments, oral administration of the compositions described herein may be advantageous.

[0098] The therapeutic agent and / or pharmaceutical preparation of the present invention can be applied in a conventional manner by any effective route. The mode of application can be systemic administration, parenteral administration, topical administration or oral administration. For example, administration can be but is not limited to parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, oral, buccal or ocular routes, or intravaginal, inhalation, long-acting injection or implantation. Therefore, the mode of administration of the composition of the present invention (alone or in combination with other drugs) can be but is not limited to sublingual administration, injection administration (including short-acting, long-acting, implantation and granular forms of subcutaneous or intramuscular injection), or by using vaginal creams, suppositories, pessaries, vaginal rings, rectal suppositories, intrauterine devices and transdermal forms, such as patches and creams.

[0099] For inhalation or intranasal administration, the pharmaceutical preparation can be delivered from a pressurized package or a nebulizer in the form of an aerosol spray. These compounds can also be delivered in the form of an emulsion, a liquid, a spray, a powder or a suppository. The reservoir of the preparation can provide the metering of the preparation. In addition, a predetermined dose can be provided, for example, a suppository form can be provided and inserted into the nasal cavity with a predetermined dose. A kit can be provided, including the dosage form and application dosage instructions of the preparation.

[0100] Suitable topical formulations for use with this embodiment may also include transdermal devices, aerosols, creams, ointments, lotions, dusting powders, gels, and the like.

[0101] dose

[0102] The therapeutic agents and / or pharmaceutical formulations described herein can be administered to a subject using any amount and any route of administration effective to treat a disease, disorder, and / or condition. The exact dosage required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease, the specific formulation, the mode of administration, the mode of activation, and the like.

[0103] In some embodiments, the formulations according to the present invention may be administered at a dosage level sufficient to deliver a therapeutic agent dose of about 0.1 mg / kg to about 500 mg / kg body weight, about 0.1 mg / kg to about 250 mg / kg body weight, about 0.1 mg / kg to about 100 mg / kg body weight, about 0.1 mg / kg to about 50 mg / kg body weight, about 0.1 mg / kg to about 10 mg / kg body weight, and / or about 0.1 mg / kg to about 5 mg / kg body weight, about 1 mg / kg to about 2 mg / kg body weight, about 1 mg / kg to about 10 mg / kg body weight, about 5 mg / kg to about 15 mg / kg, about 10 mg / kg to about 20 mg / kg body weight, about 20 mg / kg to about 30 mg / kg body weight, about 30 mg / kg to about 40 mg / kg body weight, about 40 mg / kg to about 50 mg / kg body weight, about 50 mg / kg to about 60 mg / kg body weight, about 60 mg / kg to about 70 mg / kg body weight, about 70 mg / kg to about 80 mg / kg body weight, about 80 mg / kg to about kg to about 90 mg / kg body weight, about 90 mg / kg to about 100 mg / kg body weight, about 100 mg / kg to about 110 mg / kg body weight, about 110 mg / kg to about 120 mg / kg body weight, about 120 mg / kg to about 130 mg / kg body weight, about 130 mg / kg to about 140 mg / kg body weight, about 140 mg / kg to about 150 mg / kg body weight, about 150 mg / kg to about 160 mg / kg body weight, about 160 mg / kg to about 170 mg / kg body weight, about 170 mg / kg to about 180 mg / kg body weight, about 180 mg / kg g to about 190 mg / kg body weight, about 190 mg / kg to about 200 mg / kg body weight, about 15 mg / kg to about 25 mg / kg body weight, about 25 mg / kg to about 35 mg / kg body weight, about 35 mg / kg to about 45 mg / kg body weight, about 45 mg / kg to about 55 mg / kg body weight, about 55 mg / kg to about 65 mg / kg body weight, about 65 mg / kg to about 75 mg / kg body weight, about 75 mg / kg to about 85 mg / kg body weight, about 85 mg / kg to about 95 mg / kg body weight, about 95 mg / kg to about 105 mg / kg body weight, about 105 mg / kg to about 115 mg / kg body weight, about 115 mg / kg to about 125 mg / kg body weight, about 125 mg / kg to about 135 mg / kg body weight, about 135 mg / kg to about 145 mg / kg body weight, about 145 mg / kg to about 155 mg / kg body weight, about 155 mg / kg to about 165 mg / kg body weight, about 165 mg / kg to about 175 mg / kg body weight, about 175 mg / kg to about 185 mg / kg body weight, about 185 mg / kg to about 195 mg / kg body weight, about 195 mg / kg to about 205 mg / kg body weight.

[0104] In some embodiments, the therapeutic agents described herein may be administered at a dose of about 10-50 μg / mL, 20 μg / mL, or 40 μg / mL.

[0105] In some embodiments, the therapeutic agent and / or pharmaceutical preparation of the present invention is provided with one or more dosages, and is applied to the subject once or multiple times. Some therapeutic agents and / or pharmaceutical preparations are only provided in a single application. Some therapeutic agents and / or pharmaceutical preparations are provided according to an application scheme including two or more applications. Each application can be the same dosage, or it can be different from the dosage before and / or after. In some embodiments, an initial dose (herein referred to as "loading dose") higher than the subsequent dose is provided to the subject. In some embodiments, the dosage is reduced during the application. In some embodiments, according to the needs of the subject, the application scheme includes about every 2 hours to about every 10 hours, about every 4 hours to about every 20 hours, about every 6 hours to about every 30 hours, about every 8 hours to about every 40 hours, about every 10 hours to about every 50 hours, about every 12 hours to about every 60 hours, about every 14 hours to about every 70 hours or longer application of pharmaceutical preparations.

[0106] The duration of delivery of the desired dosage can be about 5 days to 365 days, about 5 days to 300 days, about 5 days to 300 days, about 5 days to 250 days, about 5 days to 200 days, about 5 days to 100 days, about 5 days to 60 days, about days to 30 days, about 5 days to 14 days, or about 3 days to 7 days, preferably about 21 days to 28 days.

[0107] In some embodiments, the desired dose of the formulations described herein can be administered once a day or multiple times a day. For example, a treatment regimen can include administering a dosage level sufficient to deliver 10 mg / kg body weight twice a day, 20 mg / kg body weight twice a day, 50 mg / kg body weight once a day, 10 mg / kg body weight three times a day, 20 mg / kg body weight four times a day, or 50 mg / kg body weight twice a day.

[0108] joint

[0109] In some embodiments, the therapeutic agents and / or pharmaceutical preparations of the present invention can be used in combination with other active agents such as antibiotics and / or vaccines. By "combined use", it is not meant that they must be administered simultaneously and / or formulated to be delivered together, although these delivery methods are within the scope of the present invention.

[0110] In some embodiments, the invention encompasses the delivery of a pharmaceutical, prophylactic, research, or diagnostic agent in combination with an agent that increases its bioavailability, reduces and / or alters its metabolism, inhibits its excretion, and / or improves its distribution in vivo.

[0111] The preparation of the present invention and additional activating agent can be used simultaneously, sequentially or in any order. The preparation of the present invention and additional activating agent can be used with different dosages, different application frequencies and / or different routes, whichever is appropriate. As used herein, the term "simultaneous application" may mean that the preparation of the present invention and additional activating agent can be used substantially simultaneously, for example, as a mixture or in a sequence immediately thereafter. The term "sequential application" used herein may mean that the preparation of the present invention and additional activating agent can not be used simultaneously, but one by one or in groups, with a specific time interval between applications. The time interval between each application of the preparation of the present invention and additional activating agent can be the same or different, and can be selected from, for example, 2 minutes to 96 hours, 1 to 7 days or a week, two weeks or three weeks. Typically, the time interval between applications can be in the range of a few minutes to a few hours, for example, in the range of 2 minutes to 72 hours, 30 minutes to 24 hours or 1 to 12 hours.

[0112] Unless otherwise specified, all scientific and technical terms used in this application have the meanings commonly used in the art. The definitions provided herein are for the purpose of facilitating the understanding of certain terms frequently used herein and are not intended to limit the scope of this application.

[0113] Stimulate hair growth or regrowth

[0114] The present invention provides a method for stimulating hair growth and / or regeneration in a subject. The method comprises contacting a target area of ​​the subject's skin with an effective amount of a hair growth or regeneration composition, wherein the hair growth or regeneration composition comprises a nicotinamide phosphoribosyltransferase (NAMPT) protein, an active peptide fragment thereof, a NAMPT analog, a vector comprising a polynucleotide encoding a NAMPT protein, a NAMPT activator, or a combination thereof. In some embodiments, the hair growth or regeneration composition comprises a pharmaceutically acceptable carrier.

[0115] As used herein, contact refers to bringing two items into physical proximity and contact, or placing them in an environment where such contact will occur within a reasonably short period of time. For example, contacting a site with a composition comprising NAMPT includes administering the composition to a subject at or near the site (e.g., topically), allowing NAMPT to interact with the site to stimulate hair growth or regeneration. However, contact also includes systemic administration, where NAMPT is brought into contact with the target area through circulation-mediated contact.

[0116] As used herein, hair growth refers to stimulating hair growth in a target area of ​​the skin that may not have had hair previously, or where more hair is desired simply by personal choice. Hair regrowth, on the other hand, refers to the restoration of hair levels after hair loss, such as hair loss caused by alopecia. The amount of hair growth or regrowth stimulated can vary from an increase in hair volume of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or 100% or more. Hair growth also includes stimulating the growth and / or regeneration of hair follicles.

[0117] Nicotinamide phosphoribosyltransferase

[0118] In some embodiments, the hair growth and regeneration composition comprises a NAMPT protein, an active peptide fragment thereof, or a NAMPT analog. Nicotinamide phosphoribosyltransferase (NAMPT) is an enzyme encoded by the NAMPT gene in humans. Samal et al., Molecular and Cellular Biology.14(2):1431-1437(1994). NAMPT was previously known as pre-B cell clone enhancer factor 1 (PBEF1) or extracellular form of visfatin (eNAMPT), also known as NMN pyrophosphorylase or NMN synthase. NAMPT is present in all tissues of mammals, and its coding sequence is highly conserved. McGlothlin et al., Biochem.Genet.43,127-141(2005). NAMPT has a molecular weight of approximately 55 kDa and is primarily composed of 491 amino acids. Its x-ray crystal structure has been recorded and confirmed to be a dimer of type II phosphoribosyltransferase.

[0119] The amino acid sequence of human NAMPT is shown in SEQ ID NO: 1, as shown below. See Samal et al., Mol Cell Biol., 14(2): 1431-1437 (1994).

[0120] origin

[0121] 1mnpaaeaefn illatdsykv thykqyppnt skvysyfecr ekktensklrkvkyeetvfy

[0122] 61glqyilnkyl kgkvvtkeki qeakdvykeh fqddvfnekg wnyilekydg hlpieikavp

[0123] 121egfviprgnv lftventdpe cywltnwiet ilvqswypitvatnsreqkk ilakyllets

[0124] 181gnldgleykl hdfgyrgvss qetagigasahlvnfkgtdtvaglalikkyygtkdpvpgy

[0125] 241svpaaehsti tawgkdhekd afehivtqfs svpvsvvsds ydiynaceki wgedlrhliv

[0126] 301srstqaplii rpdsgnpldt vlkvleilgk kfpvtenskg ykllppylrv iqgdgvdint

[0127] 361lqeivegmkq kmwsieniafgsgggllqkl trdllncsfk csyvvtnglg invfkdpvad

[0128] 421pnkrskkgrl slhrtpagnfvtleegkgdl eeygqdllhtvfkngkvtks ysfdeirkna

[0129] 481qlnieleaah h

[0130] / /

[0131] NAMPT protein, its peptide fragment, mutant, truncation, derivative, analog and splice variant show the NAMPT activity that is substantially the same as wild-type protein or changes, and are also considered to be useful in the present invention. These variations may be intentional, for example, modifications obtained by site-directed mutagenesis, or may be accidental, such as variations obtained by mutations in the host of the NAMPT protein producer. The scope of these terms includes the NAMPT protein specifically cited herein, as well as all substantially homologous analogs and allelic variants.

[0132] Analogs can be prepared by replacing conservative amino acids. "Conservative amino acid replacement" refers to that an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine and isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan esters and histidine). Therefore, the non-essential amino acid residues predicted in the NAMPT protein are preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be randomly introduced along all or part of the NAMPT coding sequence, such as by saturation mutagenesis, and the activity of the resulting mutants can be screened to identify mutants that retain activity. After mutagenesis of the nucleotide sequence of NAMPT, the encoded protein can be recombinantly expressed and the activity of the protein can be determined. In some embodiments, the composition comprises a NAMPT analog that is at least 70% identical to SEQ ID NO: 1.

[0133] A "non-essential" amino acid residue is one that can be altered from the wild-type sequence of GPNMB without abolishing or, more preferably, substantially altering the biological activity, whereas an "essential" amino acid residue would result in such a change. For example, it is predicted that conserved amino acid residues in the polypeptides of the invention are particularly difficult to alter.

[0134] As used herein, an "active peptide fragment" of a NAMPT protein includes a fragment of a NAMPT protein that retains enzymatic activity. The biologically active portion of a NAMPT protein includes a peptide comprising an amino acid sequence that is sufficiently homologous to or derived from the NAMPT protein amino acid sequence, the amino acid sequence comprising fewer amino acids than the full-length GPNMB protein, and exhibiting at least one activity of the GPNMB protein. The biologically active portion of a GPNMB protein can be a polypeptide having a length of, for example, 50, 100, 200, or 300 or more amino acids.

[0135] In some embodiments, the composition comprises a NAMPT activator. A NAMPT activator is a compound that increases NAMPT activity. Many NAMPT activators have been identified. See Wang et al., Eur J Med Chem., 236: 114260 (2022). In some embodiments, the NAMPT activator is selected from 3,6-dibromo-α-[(phenylamino)methyl]-9H-carbazole-9-ethanol (P7C3) (Wang et al., Cell, 158 (6), 1324-1334 (2014)) and 1-[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)-phenyl]-3-pyridin-4-ylmethylurea (SBI-797812). In some embodiments, the composition comprises a NAMPT protein and a NAMPT activator.

[0136] In some embodiments, the composition further comprises a nicotinamide adenine dinucleotide (NAD) precursor. NAD precursors include tryptophan, nicotinic acid (pyridine-3-carboxylic acid), nicotinamide (nicotinamide), nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR).

[0137] Candidate agents can be tested in animal models. Typically, the animal model is a model for studying hair growth. Studying hair growth in an animal model (e.g., mice) is a commonly accepted practice for studying hair growth or regeneration in humans. Results are typically compared between control animals treated with the candidate drug and control littermates that did not receive the treatment. Candidate agents can be used in these animal models to determine whether the candidate agent increases the rate of hair growth or regeneration. Candidate agents can also be evaluated for their ability to increase NAMPT activity.

[0138] In some embodiments, the composition comprises a vector comprising a polynucleotide encoding a NAMPT protein. Examples of vectors include viral vectors and plasmids. The polynucleotide can be a DNA sequence or an RNA sequence. In a further embodiment, the NAMPT protein encoded by the polynucleotide is consistent with SEQ ID NO: 1.

[0139] Various pharmaceutically acceptable carriers are described herein. In some embodiments, the pharmaceutically acceptable carrier comprises a hydrogel. The hydrogel may comprise a hydrogel formed from a variety of different polymers. In the medical field, many proprietary hydrogel formulations are known. In certain embodiments, a hydrogel sheet of a cross-linked polymer gel is used. It is contemplated that hydrogels from various sources will be used with the methods and compositions of the present invention, including but not limited to commercially available hydrogels.

[0140] In some embodiments, the hydrogel includes a thermosensitive hydrogel. Thermosensitive hydrogels are polymer aqueous solutions that are converted into gels by changes in ambient temperature, resulting in in situ hydrogel formation. Examples of thermosensitive hydrogels include chitosan and related derivatives, poly(N-isopropylacrylamide)-based (PNIPAAM) copolymers, poly(ethylene oxide) / poly(propylene oxide) (PEO / PPO) copolymers and their derivatives, and polyethylene glycol / biodegradable polyester copolymers. Gong et al., Curr Med Chem 20(1): 79-94(2013). In some embodiments, the thermosensitive hydrogel is pluronic-F127, also known as poloxamer 407, which is a triblock copolymer consisting of a central hydrophobic block of polypropylene glycol and two hydrophilic blocks of polyethylene glycol (PEG).

[0141] The method of stimulating hair growth or regeneration comprises the step of contacting a target area of ​​a subject's skin with an effective amount of a hair regeneration composition. In some embodiments, the target area of ​​the skin is skin affected by hair loss. As is well known, hair is a specialized keratinized structure derived from or protruding from the epidermal epithelial invagination observed in animals, including mammals, including fur.

[0142] Hair loss (i.e., baldness or thinning hair) occurs in areas where hair was originally present. Hair loss includes hair loss caused by any reason. Hair loss also includes thinning hair, baldness, male and female pattern baldness, thinning eyelashes, and thinning eyebrows. The term includes total or partial hair loss, shedding, or any reduction in the number of hair follicles or anagen follicles in any part of the body where hair normally exists. In some embodiments, the skin affected by hair loss is part or all of the subject's scalp.

[0143] In some embodiments, the method further comprises the step of promoting the skin penetration of the target area using a skin penetration enhancer. Skin penetration enhancers include physical and chemical skin penetration enhancers. For example, physical skin penetration enhancers can be selected from needles (e.g., multiple needles), abrasive materials, or applying high pressure to the skin. Alternatively, chemical skin penetration enhancers can be used. Examples of chemical skin penetration enhancers include olein (glyceryl monooleate), isopropyl myristate, methyl laurate, N-lauroyl sarcosine, oleic acid (octadecenoic acid), sodium dodecyl sulfonate, and sodium octyl sulfate. Skin penetration enhancers can be applied to the target area to promote NAMPT and its active peptide fragments, NAMPT analogs, vectors comprising RNA encoding NAMPT protein, or NAMPT activators to pass through the skin of the target area.

[0144] In some embodiments, the method further comprises the step of creating a boundary around the target area to limit the activity of NAMPT within the target area. The boundary corresponds to the periphery of the target area, or the dividing line between the target area and the non-target area of ​​the skin. Physical or chemical means can be used to create a boundary to prevent NAMPT and its active peptide fragments, NAMPT analogs, vectors containing RNA encoding NAMPT protein, or NAMPT activators from exceeding the target area, thereby preventing the increase of NAMPT activity outside the target area. For example, a boundary is formed by placing a compound that inhibits NAMPT, such as a small molecule inhibitor or an anti-NAMPT antibody, at the boundary.

[0145] Administration of NAMPT

[0146] The present invention includes contacting the target area with an effective amount of a hair growth or regeneration composition, the composition comprising a NAMPT protein, an active peptide fragment thereof, a NAMPT analog, a vector comprising a polynucleotide encoding a NAMPT protein, a NAMPT activator or a combination thereof. Due to systemic or local administration to the subject, the target area can be contacted with the composition.

[0147] As used herein, the terms "localized" and "local" refer to the involvement of a limited area. Thus, local treatments involve treatment of a specific, limited area, in contrast to "systemic" treatments, which typically involve the entire body via the vascular and / or lymphatic systems. Thus, in some embodiments, a region is treated locally using the methods and compositions of the present invention. In some embodiments, a pharmaceutically acceptable carrier comprises a topical formulation. Topical administration refers to application to surfaces such as the skin, mucous membranes, internal organs, and the like.

[0148] In some embodiments, the hair regeneration composition includes a pharmaceutically acceptable carrier to facilitate administration. The active agent (e.g., NAMPT or NAMPT agent) is preferably used together with one or more pharmaceutically acceptable carriers and optionally any other therapeutic ingredients. The carrier must be pharmaceutically acceptable, i.e., it is compatible with the other ingredients of the formulation and does not cause excessive harm to its recipient. The active agent is provided in an amount effective to achieve the desired pharmacological effect (i.e., hair growth or regeneration) and is provided in an amount suitable for achieving the desired daily dose.

[0149] Typically, NAMPT will be suspended in sterile saline for therapeutic use. The pharmaceutical composition may alternatively be formulated to provide local or systemic sustained release of NAMPT. Many suitable drug delivery systems are known, including, for example, implantable drug release systems, hydrogels, hydroxymethylcellulose, microcapsules, liposomes, microemulsions, microspheres, etc.

[0150] The pharmaceutical compositions of the present invention can be administered by any suitable means, such as orally, topically, intradermally, subcutaneously, intranasally, subcutaneously, intramuscularly, intravenously, intraarterially or parenterally. Typically, topical administration may be preferred. When administered, the hair growth or regeneration composition may be combined with other ingredients, such as carriers and / or adjuvants. NAMPT or other active ingredients may also be covalently linked to a protein carrier, such as albumin, to reduce the metabolic clearance rate of the peptide.

[0151] It will be clear to one of ordinary skill in the art that the therapeutically effective amount of NAMPT will depend, inter alia, on the regimen of administration, the unit dose of the molecule administered, whether the peptide is administered in conjunction with other therapeutic agents, the immune status and health status of the patient, the therapeutic activity of the peptide administered, and the judgment of the treating physician.

[0152] Although the appropriate dosage of the molecules of the present invention varies according to the route of administration, age, weight, sex or condition of the subject, and should ultimately be determined by a physician, in the case of oral administration, the daily dosage may generally be between about 0.01 mg to about 500 mg per kg body weight, preferably about 0.01 mg to about 50 mg, more preferably about 0.1 mg to about 10 mg. In the case of parenteral administration, the daily dosage is generally about 0.001 mg to about 100 mg per kg body weight, preferably about 0.001 mg to about 10 mg, more preferably about 0.01 mg to about 1 mg. The daily dosage can be administered, for example, in a typical regimen of 1-4 separate administrations per day. The administered dosage can also be measured by using a target serum concentration. For example, in some embodiments, a dosage can be administered to provide a serum concentration of 100 ng / mL to 1000 ng / mL, 200 ng / mL to 800 ng / mL, 300 ng / mL to 500 ng / mL, or at least 400 ng / mL. Various considerations for determining an effective amount are described, for example, in Goodman and Gilman, The Pharmacological Bases of Therapeutics, 8th ed., Pergamon Press, 1990, and Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, Pa., 1990.

[0153] As is well known, NAMPT can be dissolved, dispersed or mixed in a pharmaceutically acceptable excipient that is compatible with the active ingredient. Suitable excipients are, for example, water, saline, phosphate buffered saline (PBS), glucose, glycerol, ethanol, etc. and combinations thereof. Other suitable carriers are well known to those skilled in the art. In addition, if necessary, the composition may contain a small amount of auxiliary substances, such as a wetting agent or emulsifier, a pH buffer.

[0154] In some embodiments, a single dose of NAMPT is administered. However, in other embodiments, NAMPT, NAMPT analogs, NAMPT active peptide fragments, vectors containing RNA encoding NAMPT proteins, or NAMPT activators are administered repeatedly or continuously over a considerable period of time. This can be achieved by repeated administration or using a sustained-release formulation.

[0155] The following examples are for illustration only and are not intended to limit the scope of the appended claims.

[0156] Example 1: NAMPT promotes hair growth

[0157] Intradermal injection of NAMPT into the mouse skin every 48 hours significantly promoted hair growth at 10 and 14 days compared with the control group ( Figure 1A Histological analysis showed that NAMPT-treated mice had increased skin hair follicles compared with the control group ( Figure 1B ).

[0158] To quantify Figure 1A ,like Figure 1B As shown, hair follicles were counted manually (by eye) in a non-blind manner at 200-fold magnification from 15 fields in each group. The number of hair follicles in the NAMPT group was significantly increased compared to the control group. The average number of hair follicles per field of view in the NAMPT group was 33.93. The average number of hair follicles per field of view in the control group was 27.47. The difference in the number of hair follicles per field of view between the NAMPT group and the control group was statistically significant (p-value of unpaired t-test was 0.0097 (GraphPad Prism 9)).

[0159]

[0160]

[0161] The complete disclosures of all patents, patent applications, and publications cited herein, as well as electronically available materials, are incorporated herein by reference. Any disagreement between the material incorporated by reference and the specification is subject to the specification. The above specific embodiments and examples are only for clear understanding. No unnecessary limitations should be construed therefrom. The present invention is not limited to the exact details shown and described, as variations obvious to those skilled in the art will be included in the invention defined by the claims.

[0162] NAMPT and wound healing

[0163] Diabetes is a systemic disease that affects multiple organs, including the skin. Approximately one-third of patients with diabetes suffer from skin diseases. Non-infectious skin diseases in patients with diabetes include pruritus, necrosis lipoidis, granuloma annulare, and Bucshke's scleredema (diabetic scleroderma). Diabetic skin is also more susceptible to bacterial and fungal infections. Delayed wound healing and impaired skin regeneration are significant complications of diabetes. The underlying pathophysiology, including vasculopathy (microangiopathy), neuropathy, biochemical changes, and immune alterations, lead to altered tissue homeostasis and impair the repair and regeneration of diabetic skin during wound healing.

[0164] Undifferentiated epidermal cells and fibroblasts in diabetic skin are defective compared with nondiabetic skin, which may severely impair wound healing. The reduction of stem cell markers in undifferentiated epidermal cells indicates that the regenerative potential of resident epidermal cells is impaired. The reduction of collagen expression in fibroblasts suggests that diabetic fibroblasts may not be able to quickly form granulation tissue during wound healing. Our analysis also showed that several metabolic pathways, including oxidative phosphorylation, glutathione metabolism, and glycolysis, were deficient in diabetic skin compared with nondiabetic skin.

[0165] Experimental methods

[0166] Diabetic, aged diabetic and non-diabetic mice were purchased from JAX Laboratories. Bilaterally symmetrical full-thickness wounds (reproducing complete skin tissue loss) were created on the back of mice using a biopsy punch; the wounds were treated with the disclosed therapeutic agents or control vehicle.

[0167] The inventors successfully synthesized and optimized a hydrogel containing a combination of recombinant NAMPT, NR, and NMN. Hydrogels containing various concentrations of NAMPT, NR, and NMN were prepared.

[0168] We used a splinted full-thickness excisional wound model in diabetic db / db mice and wild-type mice to demonstrate that NAMPT promotes skin regeneration and restores normal skin structure and composition. NAMPT hydrogels were applied to the wounds, and control hydrogels served as controls.

[0169] Compared with the control group, the treated wounds showed a significant increase in vascular density, vascular rings, and nets in both diabetic and nondiabetic wounds. Histology showed that the skin structure of the treated wounds was close to normal, with appropriate epithelial thickness, no scarring, basket-like arrangement of collagen, reappearance of dermal fat, regeneration of sarcolemma, and even early regeneration of sebaceous glands, similar to adjacent non-wound tissue. In contrast, the control group wounds showed collagen disorder, scarring, lack of fat and sebaceous glands, and abnormally thickened epidermal hyperplasia.

[0170] In diabetic and nondiabetic wounds, tissue analysis showed that NAMPT hydrogel treatment promoted skin regeneration, including regeneration of hair follicles, sebaceous glands, adipose tissue, myofascial membranes, and collagen in a scar-free pattern. NAMPT hydrogels also promoted robust angiogenesis in wounds of nondiabetic and diabetic mice, promoting regeneration of newly formed skin. Immunohistochemistry showed a significant increase in keratin 15 and beta-catenin in NAMPT-treated diabetic wounds compared with control diabetic wounds, which is consistent with our scRNAseq findings. The increase in beta-catenin indicates increased activation of Wnt signaling. These findings confirm our scRNAseq findings, including increased epidermal stem cell numbers and activity, and enhanced sebaceous gland and hair follicle formation as indicated by lineage analysis. We observed basketweave collagen deposition without scar formation in NAMPT-treated wounds, which was confirmed by increased activity of wound-reactive fibroblasts and regenerative signals such as Wnt, as shown by scRNAseq.

[0171] As shown above, NAMPT hydrogel promoted complete skin regeneration in both diabetic and non-diabetic wounds; the regenerated tissue was indistinguishable from adjacent skin and included complete hair follicle and gland regeneration. Macroscopic examination showed that vascularization in the treated wounds was significantly more numerous and larger, present in the dermis and also extending from the subcutaneous tissue to the wound surface, indicating that the disclosed treatment also promoted the participation of the subcutaneous tissue in skin regeneration. In addition, the treated wounds contained more subcutaneous fat compared to the control group. The control group wounds showed significant inflammation and a thick scar collagen pattern, with minimal skin fat formation, minimal hair follicles, and minimal glands.

[0172] In diabetic mice, treatment with NAMPT hydrogel increased blood vessels and granulation tissue. Complete regeneration of skin architecture was present, including a regenerated dermis (non-scarred dermis) with glands, vasculature, hair follicles, and intradermal adipose tissue. Control diabetic wounds showed little dermal formation and minimal tissue regeneration. The inventors have demonstrated for the first time that topical NAMPT can rescue damaged diabetic skin regeneration, including angiogenesis, granulation, and re-epithelialization.

[0173] The inventors have demonstrated for the first time that NAMPT alone or in combination with NAD precursors is sufficient to regenerate all tissues of the skin in both non-diabetic and diabetic states. The inventors have formulated for the first time a combination of NAMPT, NR and NMN in a clinically configurable hydrogel for complete skin regeneration without scarring.

[0174] The novel NAMPT-containing hydrogel promoted an increase in vascular density and vascular rings, leading to complete skin regeneration with glands, hair follicles, blood vessels, fat, muscle, basket-weaving collagen, and inhibited the formation of scar-pattern collagen.

[0175] The novel NAMPT-containing hydrogel resulted in complete skin regeneration with glands, vasculature, hair follicles, and intradermal adipose tissue.

[0176] Example 3: Efficient delivery of NAMPT

[0177] The inventors are further developing clinically configurable methods to provide the disclosed treatments, including testing novel high-efficiency in vivo lipid nanoparticles carrying codon-optimized NAMPT mRNA alone, and in combination with PDGF, VEGF, EGF, SIRT1 and other mRNAs. These lipid nanoparticles are injected at the site of skin defects or embedded in hydrogels for sustained release.

[0178] Example 4: NAMPT formulation with NR and NMN

[0179] The inventors also tested NR and NMN liposomal formulations within hydrogels and in combination with mRNA delivery.

[0180] The findings may suggest that combination therapy is feasible and could be equally effective, or perhaps even more effective, through similar mechanisms of action.

[0181] Example 5: NAMPT formulation containing activators

[0182] The inventors are also developing first-of-its-kind NAMPT+P7C3+SBI797812 (NAMPT activator) combinations as well as single and dual formulations of P7C3 and SBI-797812 that will activate endogenous and exogenous, intracellular and extracellular NAMPT to maximize NAD. These are also in development in combination with NR and NMN.

[0183] The findings may suggest that combination therapy is feasible and could be equally effective, or perhaps even more effective, through similar mechanisms of action.

[0184] Example 6: Regulation of NAMPT expression in vivo

[0185] Finally, the inventors optimized lentiviral-based NAMPT delivery techniques to achieve local and systemic regulatable expression. The inventors anticipate that these techniques will significantly accelerate the regeneration of the skin and all tissues within it, without defects or scars.

[0186] We produce lentiviral vector-based therapies according to standard protocols. Lentiviral-based NAMPT delivery technologies for local and systemic regulatable expression. These technologies have the potential to significantly accelerate the regeneration of skin and tissues without defects and scars.

[0187] Studies conducted by the authors, including single-cell RNA sequencing, elucidated the mechanism of action of the disclosed novel treatment for complete skin regeneration and prevention of scarring.

[0188] We performed gene ontology (GO) analysis of genes differentially expressed between fibroblast clusters (clusters #0, #5, #10, and #12) to determine whether specific functions could be assigned to different fibroblast subsets ( Figure 2A -E). Cluster #0 is enriched for fibroblast proliferation and response to injury pathways, indicating that cluster #0 is the major fibroblast cluster targeted in this biological system ( Figure 2B ). Next, we performed gene ontology analysis of genes differentially expressed between NAMPT-treated and control cluster #0 fibroblasts. NAMPT-treated cluster #0 fibroblasts were enriched for extracellular matrix organization, response to cytokines, and regulation of cell migration and motility pathways, suggesting that treatment with NAMPT can mobilize this fibroblast population in diabetic wounds ( Figure 2G ). Similarly, in cluster #0 fibroblasts treated with NAMPT, the gene expressions of collagens (including Col1a1, Col1a2, Col3a1, Col5a2, and Col6a1) were significantly increased ( Figure 2F ).

[0189] Effect of NAMPT on undifferentiated epidermal cells in wounds of diabetic patients

[0190] In addition to marker-based classification, we also confirmed that cluster #1 represented undifferentiated epidermal cells through pathway enrichment. Pathway analysis showed that the gene expression signature of this cluster was involved in skin barrier establishment, cell motility, and epithelial development ( Figure 3C We performed gene ontology (GO) analysis on cluster #1 undifferentiated epidermal cells, which is the largest cluster of undifferentiated epithelial cells. This showed that NAMPT-treated wounds had an enhanced effect on wounding and cell migration, indicating that NAMPT treatment mobilized undifferentiated epidermal cells in the wound environment ( Figure 3B ). In addition, compared with the control group, cluster #1 cells treated with NAMPT expressed significantly higher levels of epidermal stem cell markers, including Krt5, Krt14, Krt15, Trp63, Itgb1, and Itga6 ( Figure 3A ). Trp63 is a p53 homologue that identifies epidermal stem cells12. Itga6 is also a marker for epidermal stem cells. Taken together, these suggest that NAMPT enhances the epidermal stem cell population and its repair function in diabetic wounds.

[0191] Pseudo-temporal lineage trajectory analysis reveals that NAMPT stimulates epidermal stem cells in diabetic wounds

[0192] To further confirm that NAMPT treatment stimulated epidermal stem cells in the diabetic model, we performed lineage trajectory analysis on cluster #1 cells. After mapping the cells and sorting them by pseudotime, we identified branch point 2 as the terminal branch point leading to two cell fates ( Figure 4A -D). Cells in NAMPT-treated wounds dominated cell fate 1, while cells in control wounds dominated cell fate 2 ( Figure 4B ). The heat map shows that the levels of Krt5, Krt14, and Krt15 expressed by wound cells treated with NAMPT were significantly increased, indicating the enrichment of the epidermal stem cell population ( Figure 4C Pseudo-time function gene mapping along both cell fates revealed and confirmed that most cells with increased expression of Krt5, Krt14, and especially Krt15 were induced only in NAMPT-treated wounds but not in control wounds ( Figure 4C and 4D The pseudotemporal directionality we observed for stem cell genes, particularly Krt15, suggests a distinct population of lineage-associated cells with increased stem cell properties that are more prevalent in NAMPT-treated wounds than in control wounds.

[0193] Pathway analysis reveals the effects of NAMPT on wounds in diabetic patients

[0194] We used the CellChat software package to infer cell-cell communication in wounds from NAMPT-treated diabetic patients versus control diabetic patients. Figure 5A showed that NAMPT treatment promoted several pathways that play key roles in epidermal stem cell function, including Wnt ( Figure 5A -D), bone morphogenetic protein (Bmp) (data not shown), and activin (data not shown).

[0195] Wnt signaling involves the binding of secreted Wnt ligands to Frizzled receptors, leading to the activation of Disheveled and the stabilization of β-catenin, which translocates to the nucleus to activate transcription. Wnt signaling plays a key role in skin development 15 Wnt signaling is required for homeostasis of the hair follicle and interfollicular epidermis by regulating stem cell populations 16,17 (The Cellchat clusters are named CLA-CLR, corresponding to clusters #0-#17; Figure 5B ). As determined by CellChat analysis, NAMPT treatment increased the diversity, number, and strength of Wnt-Fzd ligand-receptor interactions ( Figure 5A-D). In particular, increased Wnt signaling was observed in both undifferentiated and differentiated epidermal cell populations, suggesting that these cell populations are activated to promote wound healing and hair follicle regeneration. Activins are secreted ligands that mediate their biological effects by binding to transmembrane receptors, serine / threonine activin receptors. Activins are essential for skin morphogenesis, hair follicle development, and wound healing. 18-20 Bone morphogenetic proteins (BMPs) are ligands that bind to cell surface serine / threonine kinase receptors and activate Smad proteins, which translocate to the nucleus and affect transcription 21 BMP signaling is also involved in the regulation of epidermal and hair follicle stem cells 22 .

[0196] Activins, Bmps, and Wnts 16 Increased activation, particularly in epidermal cell populations after NAMPT treatment, may indicate increased regenerative signaling, such as in hair follicle formation, corroborating our histological findings (Figure 6). For example, Wnt and BMP signaling crosstalk is critical in the development of hair 23 .

[0197] Epidermal stem cells express high levels of Itgb1 24,25 Itgb1-positive epidermal cells exhibit multipotent differentiation capabilities and are dependent on Itgb1 to achieve these functions 25 Hgf through Itgb1 26 Promotes dedifferentiation of epidermal cells (increases stem cell properties), thereby accelerating wound healing. Our data suggest that NAMPT promotes Hgf signaling in the epidermal stem cell population, which also expresses higher levels of Itgb1 as a result of NAMPT treatment (Figure 3). Hgf deficiency in mesenchymal stem cells (MSCs) from diabetic patients may reduce their efficacy in wound healing 27 ; therefore, NAMPT-mediated restoration of Hgf signaling may contribute to the ability of NAMPT to promote wound healing.

[0198] We also observed that immune pathways were upregulated in NAMPT-treated diabetic wounds. For example, MHC-II, CD6, ALCAM, VISTA, MHC-I, and CD80 were enriched in NAMPT-treated diabetic wounds. This may indicate that the wound environment fights infection by enhancing antigen presentation and immune system activation.

[0199] Furthermore, we observed activation of several pro-inflammatory pathways in NAMPT-treated diabetic wounds, including TNF and IL1. TNF and IL1 are critical in promoting epidermal cell proliferation and migration in wound healing. These findings are also supported by recent findings in humans that healing diabetic foot ulcers exhibited elevated pro-inflammatory signatures compared to non-healing diabetic foot ulcers. NAMPT also increased progranulin (Grn) signaling (Figure 5). Grn has been shown to attract immune cells to the wound site and stimulate angiogenesis and cell proliferation, suggesting that it has growth factor properties. These findings suggest that NAMPT treatment may stimulate the immune system and thereby protect the diabetic wound microenvironment from infection.

[0200] In addition, we observed increased activation of colony stimulating factor (CSF3), also known as granulocyte-macrophage colony stimulating factor (GM-CSF) (data not shown). Specifically, cluster 5 (CLF) fibroblasts in NAMPT-treated wounds sent CSF3 signals to cluster 6 (CLG) macrophages, potentially enhancing CLG activation. Interestingly, we observed increased SPP1 signaling produced by NAMPT-treated CLG macrophages and targeting multiple cell populations, primarily epidermal cell populations (data not shown). Osteopontin (SPP1) has been shown to activate mesenchymal stem cells to improve wound healing. Osteopontin-deficient mice exhibited altered wound healing with breakdown of the extracellular matrix, including small-diameter collagen fibers.

[0201] Pseudo-temporal lineage trajectory analysis revealed that NAMPT stimulated hair follicle formation by stimulating keratin 79+ cells.

[0202] It has been previously demonstrated that keratin 79+ (Krt79+) epidermal cells migrate during new hair tube formation. Next, during the early stages of hair follicle differentiation, Krt79+ cells serve as early progenitors of the companion layer. These cells then become Krt79- and keratin 6+ (Krt6+). Here, we performed lineage tracing to confirm this trend in diabetic wounds. Cells were ordered pseudotemporally; Krt79+ cells appeared earlier and represented progenitors, while Krt6a+ and Krt6b+ cells appeared later and represented differentiated cells. This confirmed that the pseudotemporal directionality is biologically accurate ( Fig. 7A -C). Figure 7C The results showed that Krt79+ and Krt6a / Krt6b+ cells were enriched in NAMPT-treated wounds relative to control-treated wounds. This suggests that the differentiation process from Krt79+ to Krt6+ is induced by NAMPT treatment and contributes to the formation of hair follicles, which is consistent with and confirmed by our histological findings (Figure 6).

[0203] Pseudo-temporal lineage trajectory analysis reveals that NAMPT treatment stimulates sebaceous gland formation

[0204] Krt5+ / Krt14+ positive epidermal cells are located at the base of the sebaceous glands and represent progenitor / stem cells with the potential to differentiate into sebocytes37. During early differentiation, Krt5+ / Krt14+ cells lose Krt5, retain Krt14, and acquire Krt7937. Later in differentiation, these Krt14+ / Krt79+ cells become Pparg+ / Ar+ / Fasn+ (Pparg, peroxisome proliferator-activated receptor γ; Ar, androgen receptor; Fasn, fatty acid synthase)37. Here, we performed lineage tracing to confirm this trend in diabetic wounds. Cells were sorted in pseudotime; Krt5+ / Krt14+ cells appeared earlier and represented stem / progenitor cells, and Pparg+ / Ar+ / Fasn+ appeared later and represented differentiated sebocytes ( Fig. 8A -C). These results confirm that the pseudotemporal directionality is biologically accurate relative to the known differentiation program of progenitor cells into sebocytes. Figure 8C The results shown show that Pparg+ / Fasn+ cells are enriched in NAMPT-treated wounds compared to control wounds. This suggests that the Krt5+ / Krt14+ cell differentiation axis toward Pparg+ / Fasn+ is induced by NAMPT treatment, is largely absent in control wounds, and contributes to the formation of sebaceous glands, which is consistent with and confirmed by our histological findings (Figure 6).

[0205] Pseudo-temporal lineage trajectory analysis reveals that NAMPT stimulates the Krt77+ cell population

[0206] In mice, sweat glands are exclusively found in the paw pads38, which has hampered the study of sweat glands and their regeneration in the dorsal skin. Krt77 is a marker for eccrine sweat glands39. Krt5+ / Krt14+ progenitor cells differentiate into Krt77+ sweat gland duct cells39. Here, we performed lineage tracing to identify this differentiation pattern of sweat gland cells in diabetic wounds. Cells were sorted pseudo-temporally; Krt5+ / Krt14+ cells appeared earlier and represented stem / progenitor cells, while Krt77+ appeared later and represented sweat gland cells ( Fig.9A -C). This analysis confirmed that the pseudotemporal directionality was biologically accurate and allowed differentiation toward Krt77+ cells. Figure S4C shows an increase in Krt77+ cells in NAMPT-treated wounds compared to control wounds. This suggests that NAMPT treatment induced differentiation of Krt5+ / Krt14+ toward Krt77+ cells that was largely absent in control wounds. This molecular evidence suggests that NAMPT may promote differentiation into a Krt77+ cell population that may be associated with sweat glands.

[0207] Role of NAMPT in epidermal cell differentiation

[0208] During epidermal cell differentiation, undifferentiated basal cells characterized by Krt5+ / Krt14+ / Krt15+ differentiate into Krt1+ / Krt10+ spinous cells and finally into terminally differentiated keratinocytes (Cdsn+ / Lor+ / Ivl+)( Fig. 10A ). To investigate the role of endogenous NAMPT in epidermal differentiation, we plotted all epidermal cells from non-diabetic skin as a function of pseudotime. Undifferentiated epidermal cells appear at the beginning of the trajectory in early pseudotime. Differentiated epidermal cells appear at the end of the trajectory in late pseudotime. We confirmed that the plotted trajectories and pseudotime directionality were biologically accurate by plotting several markers as a function of pseudotime ( Fig. 10B and C). As expected, Krt5, Krt14, and Krt15 are highly expressed in undifferentiated epidermal cells at early pseudotime. As Krt5, Krt14, and Krt15 decrease, Krt1 and Krt10 increase, as expected for differentiating epidermal cells. Finally, terminal differentiation markers, including Cdsn, Lor, Ivl, and Sbsn, are enriched in differentiated cells at the end of the trajectory (late pseudotime). We observed that NAMPT levels are high in early epidermal stem cells that express high levels of Krt5, Krt14, and Krt15. The pseudotemporal decrease in NAMPT precedes the decrease in stem cell markers, suggesting that NAMPT is involved in the maintenance of stem cell properties. Interestingly, NAMPT expression increases before the increase in Krt1 and Krt10, markers of more differentiated epidermal cells, suggesting that NAMPT is also involved in the achievement of differentiation. NAMPT expression is completely lost in terminally differentiated epidermal cells that have no intrinsic stem cell properties ( Fig. 10C ).

[0209] Cell cycle analysis reveals the effect of NAMPT on wound cell proliferation in diabetic patients

[0210] Impaired cell proliferation in diabetic wounds leads to delayed granulation tissue formation and delayed re-epithelialization. We used the Tricycle software package40 to determine the effect of NAMPT on the cell cycle in diabetic wounds. Compared with the control group, NAMPT treatment increased the proportion of cells in the S phase, G2 / M phase, and M phase, indicating enhanced cell proliferation (data not shown). We confirmed our findings by running KEGG pathway analysis, which showed that NAMPT treatment significantly enhanced the "KEGG_CELL_CYCLE" pathway (data not shown). These findings were confirmed by running the HALLMARK pathway analysis, which showed that NAMPT treatment significantly enhanced the "HALLMARK_E2F_TARGETS" and "HALLMARK_MITOTIC_SPINDLE" pathways (data not shown).

[0211] Pathway analysis reveals the impact of NAMPT on wound metabolism in diabetic patients

[0212] We used KEGG pathway analysis, and the results showed that NAMPT treatment significantly enhanced the "KEGG_OXIDATIVE_PHOSPHOORYLION", "KEGG_FATTY_ACID_METABOLISM", "KEGG_CITRATE_CYCLE_TCA_CYCLE", "KEGG_MTOR_SIGNALING", and "KEGG_PYRUVATE_METABOLISM" pathways (data not shown). We further confirmed our findings using HALLMARK pathway analysis, which showed that NAMPT treatment significantly enhanced the "HALLMARK_OXIDATIVE_PHOSPHORYLATION" pathway (data not shown). These findings suggest that NAMPT increases the metabolic activity of wound tissue in diabetic patients.

[0213] NAMPT promotes skin regeneration

[0214] To confirm our findings histologically, we showed that application of NAMPT hydrogels in wounds of diabetic and non-diabetic mice enhanced skin regeneration compared to control vehicle hydrogels. Tissue analysis demonstrated that NAMPT hydrogel treatment promoted skin regeneration, including regeneration of hair follicles, sebaceous glands, adipose tissue, sarcolemmal membranes, and collagen in a non-scarring pattern (Figure 6). NAMPT hydrogels also promoted robust angiogenesis in wounds of non-diabetic and diabetic mice and promoted regeneration of newly formed skin. Immunohistochemistry showed a significant increase in keratin 15 and beta-catenin in NAMPT-treated diabetic wounds compared to control diabetic wounds, consistent with our scRNAseq findings ( Fig.6D-F). Increased β-catenin indicated increased activation of Wnt signaling. These findings corroborate our scRNAseq findings, including increased epidermal stem cell numbers and activity, and enhanced sebaceous gland and hair follicle formation as indicated by lineage analysis. We observed basketweave collagen deposition and no scarring in NAMPT-treated wounds, which was corroborated by increased activity of wound-responsive fibroblasts and regenerative signaling such as Wnt, as shown by scRNAseq.

[0215] As shown above, NAMPT treatment restored normal skin features, including sebaceous glands (SG) and hair follicles (HF), without scarring. Single-cell analysis showed that NAMPT increased the number of Krt15, Itga6, and Itgb1 epidermal stem cells (ESCs) and promoted the regenerative function of ESCs and fibroblasts in wounds. Lineage inference analysis confirmed that NAMPT promoted ESC, SG, and HF cell populations. Mechanistically, NAMPT promoted Wnt, Hgf, Csf3, and Fn1 signaling, cell migration, proliferation, metabolism, immune function, and normalization to a non-diabetic state. Immunohistochemistry confirmed that Krt15 cell populations and Wnt signaling were increased in NAMPT-treated wounds through increased β-catenin. These suggest that NAMPT has therapeutic potential in promoting ESC skin regeneration in both diabetic and non-diabetic states.

[0216] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments in accordance with the present disclosure.The scope of the present invention is not intended to be limited to the above description, but rather is set forth in the appended claims.

Claims

1. A method for stimulating hair growth and / or regeneration in a subject, the method comprising contacting a target area of ​​the subject's skin with an effective amount of a hair growth or regeneration composition, the composition comprising a nicotinamide phosphoribosyltransferase (NAMPT) protein, an active peptide fragment thereof, a NAMPT analog, a vector comprising a polynucleotide encoding a NAMPT protein, a NAMPT activator, or a combination thereof.

2. The method according to claim 1, wherein the composition comprises the NAMPT protein as shown in SEQ ID NO:

1.

3. The method of claim 1, wherein the composition comprises a NAMPT analog that is at least 70% identical to SEQ ID NO:

1.

4. The method of claim 1, wherein the composition comprises a NAMPT activator.

5. The method of claim 1, wherein the NAMPT activator is 3,6-dibromo-α-[(phenylamino)methyl]-9H-carbazole-9-ethanol (P7C3), 1-[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)-phenyl]-3-pyridin-4-ylmethylurea (SBI-797812), or a combination thereof. The method according to claim 1 , wherein the composition comprises a NAMPT protein and a NAMPT activator.

7. The method according to claim 1, wherein the composition comprises a vector comprising RNA encoding a NAMPT protein, and wherein the NAMPT protein is as shown in SEQ ID NO:

1.

8. The method of claim 1, wherein the composition further comprises an NAD precursor, and wherein the NAD precursor is selected from the group consisting of tryptophan, nicotinic acid (pyridine-3-carboxylic acid), nicotinamide (nicotinamide), nicotinamide mononucleotide (NMN), and nicotinamide riboside (NR).

9. The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

10. The method of claim 10, wherein the pharmaceutically acceptable carrier comprises a topical formulation.

11. The method of claim 10, wherein the pharmaceutically acceptable carrier comprises a hydrogel, and wherein the hydrogel is selected from the group consisting of Pluronic-F127 hydrogel, fibrin hydrogel, carboxymethylcellulose hydrogel, PEG, polysaccharides, and combinations thereof.

12. The method of claim 1, wherein the target area of ​​skin is skin affected by hair loss.

13. The method of claim 12, wherein the skin affected by hair loss is a portion or all of the subject's scalp.

14. The method of claim 1 further comprising the step of promoting skin penetration in the target area using a skin penetration enhancer selected from the group consisting of needles, abrasive materials, or application of high pressure to the skin.

15. The method of claim 1, further comprising the step of creating a boundary around the target area to restrict the activity of the NAMPT to be substantially within the target area.

16. A wound healing composition for topical use, comprising a dose of nicotinamide phosphoribosyltransferase (NAMPT) protein, an active peptide fragment thereof or a NAMPT analog, and a pharmaceutically acceptable topical carrier, wherein application of the composition to the skin of a patient promotes complete skin regeneration.

17. The wound healing composition of claim 16, wherein the topical carrier is a hydrogel selected from the group consisting of Pluronic-F127 hydrogel, fibrin hydrogel, carboxymethylcellulose hydrogel, PEG, polysaccharides, and combinations thereof.

18. The wound healing composition according to claim 16, wherein the composition further comprises a NAMPT activator.

19. The wound healing composition according to claim 18, wherein the NAMPT activator is 3,6-dibromo-α-[(phenylamino)methyl]-9H-carbazole-9-ethanol (P7C3), 1-[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl)-phenyl]-3-pyridin-4-ylmethyl urea (SBI-797812) or a combination thereof.

20. The wound healing composition of claim 16, wherein the composition further comprises an NAD precursor, and wherein the NAD precursor is selected from tryptophan, nicotinic acid (pyridine-3-carboxylic acid), nicotinamide (nicotinamide), nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR).

21. A method of treating a skin wound comprising applying a therapeutically effective amount of the composition of claim 16 to the wound of a human or animal subject.

22. The method of claim 21, wherein the pharmaceutically acceptable topical carrier is a hydrogel.

23. The method of claim 21, wherein the skin wound is a diabetic wound.

24. The method according to claim 21, wherein the wound healing composition is present in an amount of 1 mm 2 The skin wound surface area contained at least 0.01 micrograms of NAMPT protein.

25. The method according to claim 21, wherein the wound healing composition is present in an amount of 1 mm 2 The skin wound surface area contained at least 0.05 micrograms (μg) of NAMPT protein.